BIOSCRIP, INC. (NASDAQ:BIOS) Files An 8-K Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure.

On March 27, 2017, BioScrip, Inc. (the Company), issued a press
release in connection with the Companys upcoming investor
meetings, a copy of which is furnished herewith as Exhibit 99.1.
In conjunction with these meetings, the Company is publishing an
updated investor presentation to the investor relations section
of its website.

The information in this Item 7.01, including Exhibit 99.1, is
being furnished and shall not be deemed filed for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section. The
information in this Item 7.01, including Exhibit 99.1, shall not
be incorporated by reference into any registration statement or
other document to the Securities Act of 1933, as amended. The
Company undertakes no duty or obligation to publicly update or
revise the information contained in this Current Report and
cautions that the information included in this Current Report
under Item 7.01, including Exhibit 99.1, is current only as of
March 27, 2017 and may change thereafter. The furnishing of the
information in this report is not intended to, and does not,
constitute a determination or admission by the Company that the
information in this report is material or complete, or that
investors should consider this information before making an
investment decision with respect to any security of the Company.

Forward-Looking Statements

This current report includes statements that may constitute
forward-looking statements, that involve substantial risks and
uncertainties, including the statements regarding 2017 guidance,
the anticipated effects of the UnitedHealth contract termination
and other statements regarding the Companys plans and strategies.
These statements are made to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. You can
identify these statements by the fact that they do not relate
strictly to historical or current facts. In some cases,
forward-looking statements can be identified by words such as
may, should, could, anticipate, estimate, expect, project,
outlook, aim, intend, plan, believe, predict, potential, continue
or comparable terms. Because such statements inherently involve
risks and uncertainties, actual future results may differ
materially from those expressed or implied by such
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual
results may differ materially from those in the forward-looking
statements as a result of various factors. Important factors that
could cause or contribute to such differences include but are not
limited to risks associated with: the Companys ability to
integrate the acquisition of Home Solutions, the Companys ability
to grow its core Infusion revenues, the Companys ability to
continue to experience positive results from its financial
improvement plan to reduce operating costs; the Companys ability
to comply with the covenants in its debt agreements; the
UnitedHealth contract termination, including potential accounting
charges and impacts on other contract provisions and their
associated revenue; the success of the Companys initiatives to
mitigate the impact of the Cures Act on its business; reductions
in federal, state and commercial reimbursement for the Companys
products and services; increased government regulation related to
the health care and insurance industries; as well as the risks
described in the Companys periodic filings with the Securities
and Exchange Commission. The Company does not undertake any duty
to update these forward-looking statements after the date hereof,
even though the Companys situation may change in the future. All
of the forward-looking statements in this report are qualified by
these cautionary statements.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

About BIOSCRIP, INC. (NASDAQ:BIOS)

BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

BIOSCRIP, INC. (NASDAQ:BIOS) Recent Trading Information

BIOSCRIP, INC. (NASDAQ:BIOS) closed its last trading session up +0.01 at 1.84 with 587,653 shares trading hands.